Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.

Computational and structural biotechnology journal·2026

Same author

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.

Cancer research communications·2026

Same author

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Neuro-oncology advances·2026

Same author

Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.

Lung cancer (Amsterdam, Netherlands)·2026

Search research articles

Related Experiment Video

Updated: May 15, 2026

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

Insights on Oligometastatic Non-Small-Cell Lung Cancer.

Augusto Valdivia¹, Pau Mascaro-Baselga¹, Clara Salva-de Torres¹

¹Medical Oncology Department, Vall d'Hebron Hospital Universitari/Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

|August 14, 2025

Summary

Oligometastatic non-small-cell lung cancer (OMD-NSCLC) is a distinct subtype of advanced lung cancer. Research explores its definition, biomarkers, and therapies, including local ablative therapies and systemic treatments, to improve patient outcomes.

Keywords:

biomarkers immunotherapy local ablative therapies non-small-cell lung cancer oligometastasis targeted therapy

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: May 15, 2026

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Area of Science:

Oncology
Genetics

Background:

Oligometastatic non-small-cell lung cancer (OMD-NSCLC) represents a unique stage of advanced lung cancer with limited metastatic spread.
This subtype exhibits a more indolent clinical course compared to polymetastatic disease.

Purpose of the Study:

To review the current definition, diagnostic approaches, and therapeutic strategies for OMD-NSCLC.
To explore the role of biomarkers, particularly microRNAs, in distinguishing OMD-NSCLC.
To assess the integration of local ablative therapies (LAT) with systemic treatments.

Main Methods:

Narrative review of existing literature on OMD-NSCLC.
Analysis of diagnostic criteria and biomarkers.
Evaluation of clinical trial data for various treatment modalities.

Main Results:

MicroRNAs show potential in differentiating true oligometastatic states.
Local ablative therapies (surgery, radiotherapy) are primary treatments.
Integration of LAT with systemic therapies shows promise but yields inconsistent results.

Conclusions:

Refining the definition of OMD-NSCLC is crucial.
Identifying predictive biomarkers is essential for personalized treatment.
Individualized radical-intent therapy holds potential for improved outcomes in OMD-NSCLC.